<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279210</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(I)-20170048</org_study_id>
    <nct_id>NCT04279210</nct_id>
  </id_info>
  <brief_title>Platelet-rich Plasma for Stress Urinary Incontinence</brief_title>
  <official_title>The Effect of Platelet-rich Plasma on the Female Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress urinary incontinence (SUI) is defined by the International Continence Society (ICS) as
      &quot;the complaint of any involuntary loss of urine on effort or physical exertion or on sneezing
      or coughing. The treatment varies from Kegel exercise, bulking agents, vaginal LASER, to
      surgery. Platelet-rich plasma (PRP) stimulates angiogenesis, promoting vascular in-growth and
      fibroblast proliferation, enhancing wound-healing in both soft and hard tissue. PRP regulates
      tissue reconstruction and has been previously used in orthopedics and plastic surgery. The
      previous study revealed some promising results for PRP use in pelvic floor dysfunction,
      including SUI. We aim to evaluate the effect of PRP on female SUI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with SUI were enrolled. Pre-treatment evaluation included Overactive Bladder Symptom
      Score (OABSS), International Consultation on Incontinence Questionnaire-Urinary Incontinence
      Short Form (ICIQ-UI), Pelvic Organ Prolapse Distress Inventory 6 (POPDI‐6), Female Sexual
      Function Index (FSFI), Urinary Distress Inventory Short Form (UDI-6), Incontinence Impact
      Questionnaire, Short Form (IIQ-7), pelvic examination, and urodynamic study (UDS) (including
      pad test).

      10 milliliter blood was taken from each participant. The RegenKit-THT (RegenLab SA,
      Switzerland) was used to separation of plasma and blood cells. 3 milliliter PRP was extracted
      from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external
      urethral sphincter, and into endopelvic fascia. The participants received one treatment per
      month for three times. Follow-up schedule is as below: 1st month (transperineal ultrasound
      and questionnaires), 3rd month (UDS and questionnaires), 6th month (questionnaires), and 12th
      month (questionnaires).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Actual">October 3, 2018</completion_date>
  <primary_completion_date type="Actual">October 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUI</measure>
    <time_frame>3 months</time_frame>
    <description>The severity of stress urinary incontinence was measured by pad test.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>PRP Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with SUI received PRP injection into anterior vaginal wall (near external urethral sphincter) once per month for three times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Platelet-rich plasma</intervention_name>
    <description>The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.</description>
    <arm_group_label>PRP Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with SUI

          -  Age between 20 to 85 years

        Exclusion Criteria:

          -  Under anti-platelet agent treatment

          -  Under NSAIDs

          -  Platelet dysfunction syndrome

          -  Critical thrombocytopenia

          -  Hypofibrionogenaemia

          -  Sepsis

          -  Acute and chronic infections

          -  Chronic liver disease

          -  Anti-coagulation therapy

          -  History of malignancy

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng-Yu Long, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Municipal University Chung-Ho Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Billecocq S, Bo K, Dumoulin C, Aigon A, Amarenco G, Bakker E, Cornillet-Bernard M, Crétinon S, Deffieux X, Lartigues G, Loobuick M, Steenstrup B, de Tayrac R. [An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and non-pharmacological management of female pelvic floor dysfunction]. Prog Urol. 2019 Mar;29(4):183-208. doi: 10.1016/j.purol.2018.12.010. Epub 2019 Feb 23. Review. French.</citation>
    <PMID>30803873</PMID>
  </results_reference>
  <results_reference>
    <citation>Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010 Jan;21(1):5-26. doi: 10.1007/s00192-009-0976-9. Epub 2009 Nov 25. Review.</citation>
    <PMID>19937315</PMID>
  </results_reference>
  <results_reference>
    <citation>Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ; Pelvic Floor Disorders Network. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008 Sep 17;300(11):1311-6. doi: 10.1001/jama.300.11.1311.</citation>
    <PMID>18799443</PMID>
  </results_reference>
  <results_reference>
    <citation>Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol. 1997 Apr;89(4):501-6.</citation>
    <PMID>9083302</PMID>
  </results_reference>
  <results_reference>
    <citation>Pallua N, Wolter T, Markowicz M. Platelet-rich plasma in burns. Burns. 2010 Feb;36(1):4-8. doi: 10.1016/j.burns.2009.05.002. Epub 2009 Jun 21. Review.</citation>
    <PMID>19541423</PMID>
  </results_reference>
  <results_reference>
    <citation>Chrysanthopoulou EL, Pergialiotis V, Perrea D, Κourkoulis S, Verikokos C, Doumouchtsis SK. Platelet rich plasma as a minimally invasive approach to uterine prolapse. Med Hypotheses. 2017 Jul;104:97-100. doi: 10.1016/j.mehy.2017.05.018. Epub 2017 May 25.</citation>
    <PMID>28673602</PMID>
  </results_reference>
  <results_reference>
    <citation>Shirvan MK, Alamdari DH, Mahboub MD, Ghanadi A, Rahimi HR, Seifalian AM. A novel cell therapy for stress urinary incontinence, short-term outcome. Neurourol Urodyn. 2013 Apr;32(4):377-82. doi: 10.1002/nau.22301. Epub 2012 Sep 12.</citation>
    <PMID>22972395</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikolopoulos KI, Pergialiotis V, Perrea D, Doumouchtsis SK. Restoration of the pubourethral ligament with platelet rich plasma for the treatment of stress urinary incontinence. Med Hypotheses. 2016 May;90:29-31. doi: 10.1016/j.mehy.2016.02.019. Epub 2016 Mar 2. Review.</citation>
    <PMID>27063081</PMID>
  </results_reference>
  <results_reference>
    <citation>Medel S, Alarab M, Kufaishi H, Drutz H, Shynlova O. Attachment of Primary Vaginal Fibroblasts to Absorbable and Nonabsorbable Implant Materials Coated With Platelet-Rich Plasma: Potential Application in Pelvic Organ Prolapse Surgery. Female Pelvic Med Reconstr Surg. 2015 Jul-Aug;21(4):190-7. doi: 10.1097/SPV.0000000000000178.</citation>
    <PMID>25900058</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stress urinary incontinence</keyword>
  <keyword>Platelet-rich plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

